The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver Resection
Abstract
CONTEXT: Tumor recurrence is a major issue for patients with hepatocellular carcinoma (HCC) following curative liver resection. OBJECTIVE: To investigate the association between nucleoside analogue use and risk of tumor recurrence in patients with hepatitis B virus (HBV)--related HCC after curative surgery. DESIGN, SETTING, AND PARTICIPANTS: A nationwide cohort study between October 2003 and September 2010. Data from the Taiwan National Health Insurance Research Database. Among 100 938 newly diagnosed HCC patients, we identified 4569 HBV-related HCC patients who received curative liver resection for HCC between October 2003 and September 2010. MAIN OUTCOME MEASURES: The risk of first tumor recurrence was compared between patients not taking nucleoside analogues (untreated cohort, n = 4051) and patients taking nucleoside analogues (treated cohort, n = 518). Cumulative incidences and hazard ratios (HRs) were calculated after adjusting for competing mortality. RESULTS: The treated cohort had a higher prevalence of liver cirrhosis when compared with the untreated cohort (48.6% vs 38.7%; P < .001), but lower risk of HCC recurrence (n = 106 [20.5%] vs n = 1765 [43.6%]; P < .001), and lower overall death (n = 55 [10.6%] vs n = 1145 [28.3%]; P < .001). After adjusting for competing mortality, the treated cohort had a significantly lower 6-year HCC recurrence rate (45.6%; 95% CI, 36.5%-54.6% vs untreated, 54.6%; 95% CI, 52.5%-56.6%; P < .001). Six-year overall mortalities for treated cohorts were 29.0% (95% CI, 20.0%-38.0%) and for untreated 42.4% (95% CI, 40.0%-44.7%; P < .001). On modified Cox regression analysis, nucleoside analogue use (HR, 0.67; 95% CI, 0.55-0.81; P < .001), statin use (HR, 0.68; 95% CI, 0.53-0.87; P = .002), and nonsteroidal anti-inflammatory drugs or aspirin use (HR, 0.80; 95% CI, 0.73-0.88; P < .001) were independently associated with a reduced risk of HCC recurrence. Multivariable stratified analyses verified the association in all subgroups of patients, including those who were noncirrhotic (HR, 0.56; 95% CI, 0.42-0.76) and diabetic (HR, 0.52; 95% CI, 0.31-0.89). CONCLUSION: Nucleoside analogue use was associated with a lower risk of HCC recurrence among patients with HBV-related HCC after liver resection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Reducing Bias in Observational Studies Using Subclassification on the Propensity Score
Rosenbaum, P. R., & Rubin, D. B. (1984) · Journal of the American Statistical Association · doi:10.1080/01621459.1984.10478078 · Cited by 3,082
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
Validation of the national health insurance research database with ischemic stroke cases in Taiwan
Cheng, C., Kao, Y. Y., Lin, S., Lee, C., & Lai, M. L. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2087 · Cited by 1,277
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Immortal time bias in observational studies of drug effects
Suissa, S. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1357 · Cited by 584
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
Wu, J.-C., Huang, Y.-H., Chau, G.-Y., Su, C.-W., Lai, C.-R., Lee, P.-C., Huo, T.-I., Sheen, I.-J., Lee, S.-D., & Lui, W.-Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.009 · Cited by 435
Sitia, G., Aiolfi, R., Di Lucia, P., Mainetti, M., Fiocchi, A., Mingozzi, F., Esposito, A., Ruggeri, Z. M., Chisari, F. V., Iannacone, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209182109 · Cited by 317
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0917 · Cited by 294
Wu, C., Kuo, K. N., Wu, M., Chen, Y., Wang, C., & Lin, J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.07.060 · Cited by 277
Self-citationKwon, H., & Lok, A. S. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.33 · Cited by 250
Hung, I. F. N., Poon, R. T. P., Lai, C.-L., Fung, J., Fan, S.-T., & Yuen, M.-F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01872.x · Cited by 197
Poon, R. T.-P., Fan, S.-T., Lo, C.-M., Liu, C.-L., Ng, I. O.-L., & Wong, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1094 · Cited by 191
Treatment of chronic hepatitis B: Evolution over two decades
Yuen, M., & Lai, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06545.x · Cited by 164
Inhibition of Autophagy Enhances Anticancer Effects of Atorvastatin in Digestive Malignancies
Yang, P., Liu, Y.-L., Lin, Y.-C., Shun, C., Wu, M., & Chen, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1626 · Cited by 155
Self-citationRaza, H., John, A., & Benedict, S. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.06.016 · Cited by 152
Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia
Liaw, Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.003 · Cited by 132
Wu, C., Wu, M., Kuo, K. N., Wang, C., Chen, Y., & Lin, J. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0695 · Cited by 132
Self-citationKim, B. K., Park, J. Y., Kim, D. Y., Kim, J. K., Kim, K. S., Choi, J. S., Moon, B. S., Han, K., Chon, C. Y., Moon, Y. M., et al. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01625.x · Cited by 131
Kuzuya, T., Katano, Y., Kumada, T., Toyoda, H., Nakano, I., Hirooka, Y., Ito, A., Ishigami, M., Hayashi, K., Honda, T., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04707.x · Cited by 124
Grazi, G. L., Cescon, M., Ravaioli, M., Ercolani, G., Gardini, A., Gaudio, M. D., Vetrone, G., & Cavallari, A. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.17.s2.9.x · Cited by 114
Chan, A. C. Y. (2011) · Archives of Surgery · doi:10.1001/archsurg.2011.125 · Cited by 110
Wu, C., Chan, F. K. L., Wu, M., Kuo, K. N., Wang, C., Tsao, C., & Lin, J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.067 · Cited by 107
Self-citationLi, N., Lai, E. C. H., Shi, J., Guo, W., Xue, J., Huang, B. S., Lau, W. Y., Wu, M., & Cheng, S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0694-z · Cited by 106
Self-citationJang, J. W., Choi, J. Y., Bae, S. H., Yoon, S. K., Woo, H. Y., Chang, U. I., Kim, C. W., Nam, S. W., Cho, S. H., Yang, J. M., et al. (2007) · Cancer · doi:10.1002/cncr.22984 · Cited by 36
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Taiwan’s National Health Insurance Research Database: past and future
Hsieh, C.-Y., Su, C.-C., Shao, S.-C., Sung, S.-F., Lin, S.-J., Yang Kao, Y.-H., & Lai, E. C.-C. (2019) · Clinical Epidemiology · doi:10.2147/clep.s196293 · Cited by 1,213
Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database
Hsing, A. W., & Ioannidis, J. P. A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.3540 · Cited by 581
Data resource profile: the National Health Insurance Research Database (NHIRD)
Lin, L.-Y., Warren-Gash, C., Smeeth, L., & Chen, P.-C. (2018) · Epidemiology and Health · doi:10.4178/epih.e2018062 · Cited by 536
Metadata
- Authors
- Wu, C.-Y., Chen, Y.-J., Ho, H. J., Hsu, Y.-C., Kuo, K. N., Wu, M.-S., & Lin, J.-T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-11-14
- Volume
- 308
- Issue
- 18
- Pages
- 1906
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2116836111
- Cited by
- 818
- References
- 29
- FWCI
- 46.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.